Fulcrum Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Fulcrum Therapeutics Inc. (FULC) Misses Q2 EPS by 611c
August 26, 2019 7:13 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($9.21), $6.11 worse than the analyst estimate of ($3.10).
Second Quarter 2019 and Recent Business Highlights
In August 2019, Fulcrum announced that it initiated ReDUX4, its Phase 2b clinical trial evaluating losmapimod for the treatment of FSHD.In August 2019, Fulcrum announced that it initiated a Phase 2 open label clinical trial evaluating losmapimod for the treatment of FSHD.In July 2019, Fulcrum completed its initial public offering of common stock, raising $72.0 million in gross proceeds.Second Quarter 2019 Financial Results
Cash Position: As of June 30, 2019, cash and... More